Tiziana Life Sciences plc: Accustem Update

Rhea-AI Summary

Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS) has filed a Form 20-F with the SEC to finalize the distribution of shares in Accustem Sciences Limited to its shareholders in the US through the ADS program. This move will separate Accustem as an independent entity, allowing it to pursue its own listing. Shareholders can access detailed information about Accustem via the SEC report linked in the press release.

Positive

• Filing of Form 20-F with the SEC indicates progress in the distribution of Accustem shares.
• Successful completion of the share distribution will lead to Accustem becoming an independent entity.

Negative

• None.

NEW YORK and LONDON, March 30, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences. (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, is pleased to confirm that, in order to finalise the distribution of shares in Accustem Sciences Limited ("Accustem") to the holders of Tiziana shares in the US via its ADS program, it has recently filed a Form 20-F with the Securities Exchange Commission in the USA (the "SEC"). The Form 20-F (which gives full information about the business of Accustem), can be found at https://sec.report/CIK/0001850767.

Once the SEC has approved the Form 20-F (or it becomes effective), the final aspect of the distribution will be complete and Accustem will be an entirely separate entity and will move forward with plans to secure its own listing.

In the meantime, Tiziana shareholders are directed to the Accustem website at http://www.accustem.com/, where all further developments and news will be published.

For further enquiries:

United Kingdom Investors:

Tiziana Life Sciences plc (TLSA)

Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379

U.S. Investor Relations Contact:

RedChip Companies, Inc.

Dave Gentry

407-491-4498

dave@redchip.com

FAQ

What is the significance of Tiziana filing a Form 20-F for Accustem?

The filing indicates Tiziana's intent to complete the distribution of Accustem shares to its US shareholders, marking a key step in Accustem's transition to independence.

What does the distribution of Accustem shares mean for TLSA shareholders?

TLSA shareholders will receive shares in Accustem, allowing them to benefit from its future growth as an independent company.

How can I find more information about Accustem Sciences Limited?

Further information about Accustem can be found on its official website and in the SEC Form 20-F filed by Tiziana Life Sciences.

When will Accustem Sciences become a separate entity?

Accustem will become a separate entity once the SEC approves the Form 20-F, completing the share distribution process.